Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given an average recommendation of “Moderate Buy” by the ten brokerages that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $11.44.

MRVI has been the topic of a number of recent research reports. Robert W. Baird upped their target price on shares of Maravai LifeSciences from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Thursday, May 9th. Craig Hallum started coverage on shares of Maravai LifeSciences in a research report on Wednesday, April 10th. They set a “buy” rating and a $15.00 target price on the stock.

Maravai LifeSciences Stock Down 3.1 %

MRVI stock opened at $6.94 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 11.32 and a quick ratio of 10.47. The company’s 50 day simple moving average is $8.76 and its 200-day simple moving average is $7.61. Maravai LifeSciences has a 12 month low of $4.52 and a 12 month high of $13.31. The firm has a market capitalization of $1.75 billion, a PE ratio of -7.01 and a beta of 0.02.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Wednesday, May 8th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Maravai LifeSciences had a negative net margin of 47.81% and a negative return on equity of 4.28%. The company had revenue of $64.18 million for the quarter, compared to analyst estimates of $60.84 million. Equities analysts expect that Maravai LifeSciences will post -0.15 earnings per share for the current fiscal year.

Insider Transactions at Maravai LifeSciences

In other Maravai LifeSciences news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $9.81, for a total transaction of $97,520,954.94. Following the completion of the sale, the director now owns 20,150,005 shares of the company’s stock, valued at $197,671,549.05. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors have recently bought and sold shares of MRVI. 12 West Capital Management LP lifted its holdings in shares of Maravai LifeSciences by 13.8% during the 1st quarter. 12 West Capital Management LP now owns 13,202,988 shares of the company’s stock valued at $114,470,000 after acquiring an additional 1,600,000 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Maravai LifeSciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 10,038,126 shares of the company’s stock worth $87,031,000 after buying an additional 34,232 shares during the period. Mackenzie Financial Corp grew its stake in shares of Maravai LifeSciences by 4.8% in the fourth quarter. Mackenzie Financial Corp now owns 5,169,176 shares of the company’s stock valued at $33,858,000 after buying an additional 238,335 shares in the last quarter. Braidwell LP raised its holdings in shares of Maravai LifeSciences by 26.8% during the 4th quarter. Braidwell LP now owns 5,040,635 shares of the company’s stock valued at $33,016,000 after buying an additional 1,065,778 shares during the period. Finally, Pacer Advisors Inc. raised its holdings in shares of Maravai LifeSciences by 37.8% during the 4th quarter. Pacer Advisors Inc. now owns 2,955,230 shares of the company’s stock valued at $19,357,000 after buying an additional 810,957 shares during the period. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.